Next 6-12 months crucial for prediction platforms like Kalshi and Polymarkets
Investing.com - H.C. Wainwright has maintained its Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ:CNTB), representing significant upside from the current price of $1.32, following new analyses from the company’s Phase 2b asthma program. According to InvestingPro data, analyst consensus remains strongly bullish with price targets ranging from $6.00 to $7.50.
The research firm highlighted data from Connect Biopharma’s rademikibart program, describing it as a next-generation IL-4Rα antibody that demonstrated rapid onset of action and sustained lung function improvement in clinical trials.
H.C. Wainwright noted the drug’s biomarker-driven efficacy profile as a key factor reinforcing its positive outlook on the company’s prospects.
The firm expressed confidence that the new data supports its favorable view on CNTB shares and strengthens expectations for positive outcomes from the upcoming Seabreeze trials, which are scheduled to report results in 2026.
Connect Biopharma is developing rademikibart as a potential treatment option for asthma patients, with the company continuing to advance its clinical program through various stages of development.
In other recent news, Connect Biopharma Holdings Ltd has made significant announcements impacting its operations and governance. The company plans to terminate its American Depositary Receipts (ADR) program and transition to directly listing its ordinary shares on the Nasdaq Global Market. This change is expected to occur around September 2, 2025, with ADRs being exchanged for ordinary shares on a one-for-one basis. In governance updates, Connect Biopharma has expanded its board of directors from six to seven members, appointing Jim Schoeneck, who brings over 40 years of experience in the pharmaceutical sector. Schoeneck has held leadership roles at several companies, including Depomed, Inc. and currently serves as Chairman at FibroGen, Inc. and Calidi Biotherapeutics, Inc. On the analyst front, Northland has reiterated its Outperform rating for Connect Biopharma, maintaining a price target of $7.50 per share. This rating reflects the firm’s positive outlook on Connect Biopharma’s progress with its treatment pipeline for inflammatory and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.